ClinicalTrials.gg
CompletedNCT05963529Updated Nov 29, 2023

Validity of Humidity Ramp Protocols for Identifying Limits of Survivability in Heat-exposed Persons

An interventional study of Humidity-ramp protocol and Above-inflection fixed-condition exposure in Heat Stress, Heat Exposure and Temperature Change, Body, sponsored by University of Ottawa. Completed at 1 site in Canada. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by University of Ottawa · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The global populace is at growing risk of heat-related illness due to climate change and accompanying increases in the intensity and regularity of extremely hot temperatures. In heat-exposed persons, heat gain from the environment and metabolism initially exceeds the rate of heat dissipation from the skin. Heat is stored in the body, causing core and skin temperatures to rise, which in turn triggers autonomically mediated elevations in cutaneous blood flow and sweating to facilitate heat loss. If conditions are compensable, heat loss increases until it balances total heat gain. At this point, the rate of heat storage falls to zero (i.e., heat balance is achieved) and body temperature stabilizes, albeit at a level elevated from thermoneutral conditions. If, however, the maximal achievable rate of heat dissipation is insufficient to offset heat gain, conditions are uncompensable, and prolonged exposure will cause a continual rise in core temperature that can compromise health if left unchecked. The environmental limits of compensability (i.e., the temperatures/humidities above which heat balance can not be maintained) are therefore an important determinant of survival during prolonged heat exposure. Evaluating this limit and how it can be modified (e.g., by behavior or individual factors like age or sex) is an increasingly important and active field of study.

Contemporary evaluations of the environmental limits of compensability utilize "ramping protocols" in which participants are exposed to increasing levels of temperature or humidity (in 5-10 min stages) while core temperature is monitored. It is generally observed that core temperature is relatively stable (or rises slightly) in the early stages of exposure but undergoes an abrupt and rapid increase as heat stress becomes more severe. The conditions (e.g., wet-bulb temperature or wet-bulb globe temperature) at this "inflection point" are taken as the limits of compensability. That is, it is assumed that inflection corresponds to the demarcation point, below which core temperature would remain stable for prolonged periods (theoretically indefinitely if hydration is maintained) but above which heat loss is insufficient to offset heat gain, causing core temperature to rise continuously. Despite the increasing use of these protocols, no study has clearly demonstrated their validity for identifying the environmental limits of compensability. The goal of this project is therefore to assess the validity of ramping protocols for determining the ambient conditions above which thermal compensation is not possible.

Enrolled participants will complete four experimental trials in a climate-controlled chamber: one ramping protocol followed by three randomized fixed-condition exposures. In the ramping protocol, participants will rest in 42°C with 28% relative humidity (RH) for 70 min, after which RH will be increased 3% every 10 min until 70% RH is achieved. The core (esophageal) temperature inflection point will be determined. For the fixed-condition exposures, participants will rest in i) 42°C with RH \~5% below their individual inflection point (below-inflection condition), ii) 42°C with RH \~5% above their individual inflection point (above-inflection condition), and iii) 26°C with 45% RH (control condition). Comparing the rate of change in esophageal temperature between each fixed-condition exposure will provide important insight into the validity of ramping protocols for identifying the limits of compensability.

02

Conditions studied

  • Heat Stress
  • Heat Exposure
  • Temperature Change, Body
  • Temperature; Extreme, Exposure

Keywords

  • Heat wave
  • Hot weather
  • Heat strain
  • Cardiovascular strain
  • Environmental limits for compensability
  • Extreme heat events
  • Heat survivability
03

In context

Heat Stress Disorders

118 studies on the registry are indexed under Heat Stress Disorders; 45 are open to participants now.

This study's enrollment of 12 is below the median of 24 across 104 interventional studies indexed under Heat Stress Disorders.

Browse Heat Stress Disorders studies →

Lead sponsor

University of Ottawa is the lead sponsor of 125 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults.
  • Aged 18-85 years.
  • Non-smoking.
  • English or French speaking.
  • Ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Physical restriction (e.g., due to disease: intermittent claudication, renal impairment, active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis, etc.).
  • Use of or changes in medication judged by the patient or investigators to make participation in this study inadvisable (e.g., medications increasing risk of heat-related illness; beta blockers, anticholinergics, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Other
    Humidity-ramp protocol

    Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Humidity-ramp protocol

  • Experimental
    Above-inflection fixed-condition exposure

    Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Above-inflection fixed-condition exposure

  • Experimental
    Below-inflection fixed-condition exposure

    Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Below-inflection fixed-condition exposure

  • Active comparator
    Control fixed-condition exposure

    Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Control fixed-condition exposure

Interventions

  • OtherHumidity-ramp protocol

    Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which esophageal temperature (and rectal temperature and heart rate) inflect is subsequently determined.

  • OtherAbove-inflection fixed-condition exposure

    After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.

  • OtherBelow-inflection fixed-condition exposure

    After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.

  • OtherControl fixed-condition exposure

    Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.

06

What researchers measure

Primary outcomes

  1. Esophageal temperature rate of change

    Rate of change of esophageal temperature measured over the final 2-hours of heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  2. Predicted time until 40.2°C esophageal temperature

    Estimated time for esophageal temperature to reach 40.2°C, a commonly-cited criteria for severe heat-illness (e.g., heat stroke), calculated from the end-exposure esophageal temperature and its rate of change (assuming this rate of change is sustained)

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  3. Rectal temperature rate of change

    Rate of change of rectal temperature measured over the final 2-hours of heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  4. Predicted time until 40.2°C rectal temperature

    Estimated time for rectal temperature to reach 40.2°C, a commonly-cited criteria for

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

Secondary outcomes

  1. Number of participants unable to finish fixed-condition heat exposure

    Number of participants who could not complete each fixed-condition heat exposure due to participant withdrawal or achieving a core temperature of 39.5°C

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  2. Mean skin temperature rate of change

    Rate of change of skin temperature measured over the final 2-hours of heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  3. Heart rate rate of change

    Rate of change of heart rate measured over the final 2-hours of heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  4. Esophageal temperature

    Esophageal temperature at the end of the fixed-condition exposures

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  5. Rectal temperature

    Rectal temperature at the end of the fixed-condition exposures

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  6. Mean skin temperature

    Mean skin temperature at the end of the fixed-condition exposures

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  7. Heart rate

    Heart rate at the end of the fixed-condition exposures

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  8. Thermal sensation

    Self-reported thermal sensation at the end of the fixed-condition exposures using and 8-point scale ranging from neutral (0) to extremely hot (8).

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  9. Sweat rate

    Sweat rate at the end of the fixed-condition exposures (calculated via change in body weight)

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  10. Net fluid loss

    Net fluid loss estimated as the percentage change in body mass over the fixed-condition exposures.

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

Other outcomes

  1. Esophageal temperature inflection point

    Inflection point for esophageal temperature during the humidity-ramp protocol

    Time frame: During the ramp protocol (up to 2.5 hours)

  2. Rectal temperature inflection point

    Inflection point for rectal temperature during the humidity-ramp protocol

    Time frame: During the ramp protocol (up to 2.5 hours)

  3. Heart rate inflection point

    Inflection point for heart rate during the humidity-ramp protocol

    Time frame: During the ramp protocol (up to 2.5 hours)

07

Study locations

1 site
  • University of Ottawa
    Ottawa, Ontario K1N6N5, Canada
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant data will be made available upon reasonable request and signed access agreement.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be made available following publication of the primary study report.

Access criteria: Reasonable request and signed access agreement

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05963529
Responsible party
Glen P. Kenny (Full Professor, University of Ottawa) — Principal investigator
First posted
Jul 27, 2023
Start date
Jul 14, 2023
Primary completion
Sep 24, 2023
Completion
Sep 24, 2023
Last update
Nov 29, 2023

Study contacts

Robert D Meade, PhD, MPH
study director · University of Ottawa
Glen P Kenny, PhD
principal investigator · University of Ottawa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion